News - Amylin

Filter

Current filters:

Amylin

Popular Filters

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility

05-04-2013

The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results

08-11-2012

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Amylin operating loss leaps to over $30 million

27-04-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Investor Icahn slams Amylin for not revealing B-MS bid

05-04-2012

Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Byetta cleared for add-on therapy with basal insulin in EU

26-03-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) and drug major Eli Lilly (NYSE: LLY) said on Friday…

AmylinByettaDiabetesEli LillyEuropePharmaceuticalRegulation

Amylin 4th-qtr loss widens on charges

07-02-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of…

AmylinBiotechnologyBydureonByettaDiabetesFinancial

FDA finally approves Bydureon

30-01-2012

There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect

04-11-2011

Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq:…

AmylinByettaCardio-vascularDiabetesEli LillyPharmaceuticalResearch

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS

13-09-2011

A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

US FDA sets PDUFA action dates for Bydureon and peginesatide

12-08-2011

US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Amylin and Takeda drop combo obesity drug development

08-08-2011

Amylin Pharmaceuticals (Nasdaq: AMLN) and Japan’s Takeda Pharmaceutical (TSE: 4502) are discontinuing…

AmylinMetabolicsmetreleptinPharmaceuticalpramlintideResearchTakeda Pharmaceuticals

Back to top